Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 10/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | HTR2B | P41595 | 1/20 | 0.53 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.53 |
| ▸ | GBA1 | P04062 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2719094 | 0.86 | SCD (0.71) | SCDCYP2C9CYP2C19HTR2BMAPK14 | |
| SCHEMBL1384732 | 0.84 | SCD (0.71) | SCDCYP2C9CYP2C19HTR2BMAPK14 | |
| SCHEMBL27657963 | 0.84 | SCD (0.60) | SCDCYP2C9CYP2C19HTR2BMAPK14 | |
| SCHEMBL1817946 | 0.84 | SCD (0.57) | SCDCYP2C9CYP2C19HTR2BMAPK14 | |
| SCHEMBL1384531 | 0.83 | SCD (0.80) | SCDCYP2C9CYP2C19HTR2BMAPK14 | |
| SCHEMBL2466841 | 0.82 | SCD (0.61) | SCDCYP2C9CYP2C19HTR2BMAPK14 | |
| SCHEMBL1385082 | 0.81 | SCD (0.77) | SCD | |
| SCHEMBL3837592 | 0.81 | SCD (0.65) | SCDCYP2C9CYP2C19HTR2BMAPK14 | |
| SCHEMBL2466840 | 0.81 | SCD (0.67) | SCD | |
| SCHEMBL27651267 | 0.80 | SCD (0.61) | SCDGBA1ALDH1A1MEN1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090131447-A1 | COMBINATION THERAPY | XENON PHARMACEUTICALS INC. (CA) | 2009-05-21 | — | — | US | claimed |
| US-20090030008-A1 | PIPERAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2009-01-29 | — | — | US | claimed |
| CN-101163504-A | Combination therapy | XENON PHARMACEUTICALS INC (CA) | 2008-04-16 | — | — | CN | claimed |
| JP-2007500720-A | — | — | 2007-01-18 | — | — | JP | claimed |
| US-20060252767-A1 | Piperazine derivatives and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2006-11-09 | — | — | US | claimed |
| CN-1829701-A | Piperazine derivatives and their use as therapeutic agents | XENON PHARMACEUTICALS INC (CA) | 2006-09-06 | — | — | CN | claimed |
| EP-1651620-A2 | PIPERAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2006-05-03 | — | — | EP | claimed |
| WO-2005011657-A2 | PIPERAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2005-02-10 | — | — | WO | claimed |
| EP-1651620-B1 | PIPERAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2011-11-09 | — | — | EP | disclosed |
| US-8030488-B2 | Piperazine derivatives as stearoyl-coa desaturase inhibitors and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2011-10-04 | — | — | US | disclosed |
| EP-2316828-A1 | Piperazine derivatives and their use as therapeutic agents | Xenon Pharmaceuticals Inc. (CA) | 2011-05-04 | — | — | EP | disclosed |
| CN-101693697-A | Pyrizdazine derivatives and their use as therapeutic agents | XENON PHARMACEUTICALS INC | 2010-04-14 | — | — | CN | disclosed |
| US-20090131447-A1 | COMBINATION THERAPY | XENON PHARMACEUTICALS INC. (CA) | 2009-05-21 | — | — | US | disclosed |
| US-20090030008-A1 | PIPERAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2009-01-29 | — | — | US | disclosed |
| CN-101163504-A | Combination therapy | XENON PHARMACEUTICALS INC (CA) | 2008-04-16 | — | — | CN | disclosed |
| EP-1846035-A2 | COMBINATION THERAPY | XENON PHARMACEUTICALS INC. (CA) | 2007-10-24 | — | — | EP | disclosed |
| US-20060252767-A1 | Piperazine derivatives and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2006-11-09 | — | — | US | disclosed |
| WO-2006086445-A2 | COMBINATION THERAPY | XENON PHARMACEUTICALS INC. (CA) | 2006-08-17 | — | — | WO | disclosed |
| EP-1651620-A2 | PIPERAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2006-05-03 | — | — | EP | disclosed |
| WO-2005011657-A2 | PIPERAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252767-A1 | Piperazine derivatives and their use as therapeutic agents | ARG2, S1PR5, S1PR1 | SCD 17/4885CYP2C9 2522/4885CYP2C19 2640/4885 |
| US-20090030008-A1 | PIPERAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | ARG2, S1PR5, S1PR1 | SCD 17/4885CYP2C9 2522/4885CYP2C19 2640/4885 |
| US-20090131447-A1 | COMBINATION THERAPY | SCD, SCD5, ARG1 | SCD 1/4885CYP2C9 2153/4885CYP2C19 2621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.